Member Info for mulledwine

Its been a hell of a move this year

"Our planned Phase II studies will provide valuable insight into extending the use of EPODURE from treating anemia in pre-dialysis patients to treating the anemia of dialysis patients - the largest segment of the anemia market. Although it is very early, we are pleased to see that EPODURE is performing similarly in dialysis patients as it did in pre-dialysis patients, providing us further confidence in EPODURE and in the Biopump platform. While we continue our Phase IIa study in Israel, we are preparing for the launch of the larger, Phase IIb study in dialysis patients in the U.S. before the end of this year. Once completed, we believe that these studies will provide data to support the use of EPODURE in the treatment of anemia from chronic kidney disease," stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics.

CONT First Subjects Enrolled in Phase IIa Clinical Trial of EPODURE Biopumps to Treat Anemia in Patients with End-Stage Renal Disease on Dialysis MISGAV, Israel and SAN FRANCISCO (July 17, 2012) - Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG),the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the launch of its Phase IIa clinical trial in Israel of EPODURE™ Biopumps to treat anemia in patients with end-stage renal disease ("ESRD" or "kidney failure") on dialysis, through the sustained delivery of erythropoietin ("EPO"). Following the Israeli Ministry of Health's recent approval of the trial, Medgenics has enrolled and begun to treat the first two dialysis patients ever to receive EPODURE Biopumps. Enrollment is expected to continue in the coming months, with up to 20 patients being treated with EPODURE Biopumps. The study will evaluate the ability of EPODURE Biopumps to replace most or all of the injections of EPO or other erythropoietic stimulating agents ("ESAs") currently used in standard care, while maintaining the patient's blood hemoglobin level within the desired range. The current standard of care involves years of frequent EPO or ESA injections, which require patient compliance to reliably administer the drug during that time. Each injection is short-lived, typically causing extreme transient elevation of EPO in the patients' blood, followed by decline to ineffective levels within a few days, so the patient is not receiving sufficient drug until the next injection. The high transient levels of EPO in the blood are a source of safety concern to the U.S. Food and Drug Administration ("FDA") as well as to many medical experts.

First Subjects Enrolled in Phase IIa Clinical Trial of EPODURE Biopumps to Treat Anemia in Patients with End-Stage Renal Disease on Dialysis MISGAV, Israel and SAN FRANCISCO (July 17, 2012) - Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG),the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the launch of its Phase IIa clinical trial in Israel of EPODURE™ Biopumps to treat anemia in patients with end-stage renal disease ("ESRD" or "kidney failure") on dialysis, through the sustained delivery of erythropoietin ("EPO"). Following the Israeli Ministry of Health's recent approval of the trial, Medgenics has enrolled and begun to treat the first two dialysis patients ever to receive EPODURE Biopumps. Enrollment is expected to continue in the coming months, with up to 20 patients being treated with EPODURE Biopumps. The study will evaluate the ability of EPODURE Biopumps to replace most or all of the injections of EPO or other erythropoietic stimulating agents ("ESAs") currently used in standard care, while maintaining the patient's blood hemoglobin level within the desired range. The current standard of care involves years of frequent EPO or ESA injections, which require patient compliance to reliably administer the drug during that time. Each injection is short-lived, typically causing extreme transient elevation of EPO in the patients' blood, followed by decline to ineffective levels within a few days, so the patient is not receiving sufficient drug until the next injection. The high transient levels of EPO in the blood are a source of safety concern to the U.S. Food and Drug Administration ("FDA") as well as to many medical experts.

http://www.investegate.co.uk/Article.aspx?id=201207171543418792H

FIRST QUANTUM TEMPORARILY SUSPENDS OPERATIONS AT ITS GUELB MOGHREIN MINE First Quantum Minerals Ltd. ("First Quantum" or the "Company", TSX Symbol "FM", LSE Symbol "FQM") today announced that it has temporarily suspended normal operations at its Guelb Moghrein copper-gold mine in Mauritania due to illegal strike action by some unionized employees. The Company continues to work through a government-facilitated mediation process to achieve a resolution to the illegal strike and will update stakeholders as warranted.

http://www.investegate.co.uk/Article.aspx?id=201207171414058578H

Louise Makin, Chief Executive Officer, commented: "We have made a strong start to the new financial year and there is good momentum across the business. Our Acute Care and Interventional Medicine sales and support teams are performing well and the Varisolve® team is fully engaged with the regulatory submission. During the second half of 2012, we anticipate top-line results from AstraZeneca's Phase IIb study of AZD9773 in severe sepsis and the first results from our PARAGON Bead® studies, which are an important step towards a planned regulatory Phase II study in metastatic colorectal cancer. We are in a good position to continue to build our business both through organic development and expansion and through licensing and acquisition activities." BTG's Annual General Meeting takes place at 2pm today at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.

BTG plc: Interim Management Statement London, UK, 17 July 2012: BTG plc (LSE: BTG), the specialist healthcare company, today announces its interim management statement for the period from 1 April 2012 to 16 July 2012. Trading within the Specialty Pharmaceuticals and Interventional Medicine business areas has been in line with the Board's expectations. Revenue in the Licensing & Biotechnology business area is ahead of expectations following receipt of a $22m final royalty payment from Pfizer relating to BeneFIX® (factor IX). As a result, BTG is raising its revenue estimate for the year ended 31 March 2013 from previous guidance of £180m-£190m to £190m-£200m including total BeneFIX® revenue of c. £14m. The Group continues to make good clinical and commercial progress. Following positive data from the two pivotal US Phase III trials of Varisolve® (polidocanol endovenous microfoam (PEM)), regulatory and manufacturing development activities are continuing while compiling a New Drug Application, which BTG aims to submit in the US at the end of 2012. In June 2012, the US Food and Drug Administration (FDA) granted humanitarian use device designation for BTG's PRECISION Bead® for the treatment of patients with uveal melanoma with hypervascularised hepatic metastases. An application for a Humanitarian Device Exemption, the next step towards a potential marketing approval for this indication, is currently being prepared. The US nationwide roll-out of Voraxaze® (glucarpidase), a treatment for life-threatening high-dose methotrexate toxicity due to impaired renal function, was completed following its launch at the end of April 2012 and initial sales have been in line with expectations. Among partnered programmes, in June 2012 Sanofi submitted a supplemental Biologics License Application to the FDA and a marketing authorisation application to the European Medicines Agency seeking approval of Lemtrada™ (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS). Also in June 2012, Janssen Research & Development, LLC submitted a supplemental New Drug Application to the FDA and Janssen-Cilag International NV submitted a type II variation to the European Medicines Agency for Zytiga® (abiraterone acetate), seeking to extend its use administered with prednisone to include the treatment of patients with metastatic castration resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and before chemotherapy.

http://www.investegate.co.uk/Article.aspx?id=201207170700057880H

Jeswant Natarajan, CEO of the Company, stated: "I am delighted we have made our first major investment and especially to be investing jointly with such a significant and well capitalised partner in YZJ Holdings. We believe that the offshore marine construction industry will be a lucrative one for Creon and we anticipate building YZJ Offshore into one of the major forces within it. There remains a lot of work to do to complete the New Yard but in the interim, we are confident that we can secure some early orders for our rig designs and look forward to updating shareholders on our progress."

Introduction The Directors of Creon are delighted to announce that the Company has entered into a joint venture with multi-billion dollar China based shipbuilding giant, Yangzijiang Shipbuilding (Holdings) Pte Ltd ("YZJ Holdings"), in the offshore oil and gas infrastructure sector ("JV Agreement"). Under the terms of the JV Agreement, Creon and YZJ Holdings will each invest into the joint venture company, YZJ Offshore Engineering Pte Ltd ("YZJ Offshore"), a Singapore registered company recently set up by YZJ Holdings to be a leading player in the design and construction of marine offshore oil and gas vessels (jack-up and semi-submersible rigs) ("the Investment"). Creon will invest US$15.33 million, with YZJ Holdings and its associates investing a further US$14.67 million, into YZJ Offshore. The Investment is Creon's first significant investment under its Investment Policy and represents a major endorsement of Creon's management and access to expertise and partners in the oil and gas infrastructure sector.

http://www.investegate.co.uk/Article.aspx?id=201207170700057884H

..............................The next update is due soon, on 24 July: an interim management statement for the May to July period, which last year showed group sales edging down just 1.5%; the impact on the shares at that time being the wider market under stress. This time it will be an interesting test of the maxim "value will out" when shares try to defy fundamentals either on the upside or downside. Active traders on the short side may already be aware Carpetright's price is gradually weakening and the next update may be quite a crux for sentiment.

http://www.iii.co.uk/articles/43508/stock-watch-carpetright

Canaccord Genuity retained its "buy" stance on CSR (CSR) with a 275p target price. The broker expects the semiconductor manufacturer to report second quarter revenues of 252.1 million dollars (162.4 million pounds) and an upbeat full year outlook, when it releases results on 24th July. Canaccord expects to see a good contribution from the cameras division, benefiting from the acquisition of Zoran, noting that the firm has a number of major customers, such as Nokia and Samsung. On the broker's forecasts, the shares trade on a prospective earnings multiple of 12.3 times for 2012, falling to 12.2 times in 2013

Daniel Stewart maintained its "buy" rating for RM (RM.) with a target price of 130p. The teaching software developer completed a planned restructuring, with the broker noting a 13 million pound reduction in borrowings and a 17% cut in staff as it disposed of loss making businesses. Therefore, while Daniel Stewart forecasts a 10.5% decline in revenues for 2012 to 313.9 million pounds, the broker expects earnings per share to increase to 11p, from 7.2p for 2011.

Panmure Gordon reiterated its "sell" recommendation for Mitchells & Butlers (MAB) with a 225p target price. The pub chain is due to issue a trading update for the 42 weeks ended 14th July and the broker expects like-for-like sales growth to be dampened by the wet weather. Panmure forecasts growth of 1.5%, down from 2% in the first 33 weeks, and raised concerns over declining profit margins as the group faces increased energy and food costs. On the broker's forecasts, the shares trade on and EV/EBIDAR multiple of 7.2 times for 2012, in-line with its peer group, but the broker believes that weak top-line performance warrants a discount

Essar Oil notes Supreme Court order regarding sales tax petition July 17 2012: Essar Energy plc [LSE: ESSR], the India-focused integrated energy company, today announced that its subsidiary Essar Oil has today been directed by the Supreme Court of India to pay Rs.10 billion (c.US$182 million) to the Government of Gujarat by July 30 in relation to its deferred sales tax liability. The Court also today ruled that once the Rs.10 billion has been paid, any other coercive steps being taken by the Government of Gujarat to force immediate payment of the remaining principal amount owed, of Rs.51.69 billion (c.US$939 million) would be stayed. Essar Oil is seeking guidance from the Supreme Court on a repayment schedule and the waiver of interest in relation to the deferred sales tax liability of Rs.61.69 billion (c.US$1.12 billion). Essar Oil had offered to pay the Rs.10 billion (US$182 million) sum as part of its submission to the Supreme Court, which is due to hear Essar Oil's petition on July 31 2012. As previously announced, Essar Oil is also in advanced discussions with Indian lenders to put in place a Rs.50 billion (c.US$909 million) loan facility as a contingency measure for use in the event that the sales tax liability becomes payable immediately or that Essar Oil is not able to negotiate a satisfactory repayment schedule. This facility is expected to be finalised shortly.

http://www.investegate.co.uk/Article.aspx?id=201207171112518438H